Some mechanisms for modulating cancer signaling and metabolic pathways with EGCG have been proposed based on numerous studies in cells, such as TNF, PI3K/Akt/mTOR, p53, p38 MAPK, and NF‐κB pathways (Chan, Lee, Wang, Yeh, & Liang, 2018; Elguindy, Yacout, El Azab, & Maghraby, 2016; Li et al., 2016; Rady et al., 2018; Wang, Wang, Wan, Yang, & Zhang, 2015). This evidence concerns the gene AKT1 and cancer.